<DOC>
	<DOCNO>NCT01823315</DOCNO>
	<brief_summary>The investigator conduct trial determine whether methotrexate single-dose treatment methotrexate/Actinomycin-D single-dose treatment work well multiple course single agent chemotherapy low-risk gestational trophoblastic neoplasia .</brief_summary>
	<brief_title>Methotrexate Single-dose Treatment Methotrexate/Actinomycin-D Single-dose Treatment Low-Risk Gestational Trophoblastic Neoplasia</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>Patients FIGO Stage I , II , III criterion lowrisk gestational trophoblastic neoplasia ( GTN ) ; WHO risk score 06 ; Age≤60 year ; female , Chinese woman ; Initial treatment chemotherapy ; patient receive prior lowdose methotrexate treatment ectopic pregnancy eligible study ; Performance status : Karnofsky score≥60 ; Laboratory test : WBC≥3.5×10 ( 9 ) /L , ANC≥1.5×10 ( 9 ) /L , PLT≥80×10 ( 9 ) /L , serum bilirubin≤ 1.5 time upper limit normal , transaminase≤ 1.5 time upper limit normal , BUN , Cr≤ normal Provide write informed consent . Patients unconfirmed diagnosis GTN ; Patients placentalsite trophoblastic tumor ( PSTT ) epithelioid trophoblastic tumor ( ETT ) WHO risk score &gt; 6 ; With severe uncontrolled internal disease , unable receive chemotherapy ; Concurrently participate clinical trial Unable unwilling sign informed consent ; Unable unwilling abide protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>